Literature DB >> 6254300

Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin).

J Sandow, W von Rechenberg, G Jerzabek, K Engelbart, H Kuhl, H Fraser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6254300     DOI： 10.1530/acta.0.0940489

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN： 0001-5598


× No keyword cloud information.
  5 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.

Authors:  J G Klijn
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

3.  Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Authors:  J G Klijn; F H de Jong; M A Blankenstein; R Docter; J Alexieva-Figusch; J Blonk-van der Wijst; S W Lamberts
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

4.  Effect of in vivo pre-treatment with oestradiol and either GnRH, GnRH agonistic analog or GnRH antagonistic analog on GnRH-stimulated secretion of LH in vitro.

Authors:  G A Schuiling; T R Koiter; H Moes
Journal:  Experientia       Date:  1991-07-15

5.  Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.

Authors:  K Stoeckemann; J Sandow
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.